Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 MilliporeSigma, SystImmune Partner for Bi-specific Antibody Development | Contract Pharma
Breaking News

MilliporeSigma, SystImmune Partner for Bi-specific Antibody Development

CHOZN expression system to be used to accelerate development timelines

MilliporeSigma said that its CHOZN expression system will be used by SystImmune, a Seattle-based biotechnology company, for commercial development of a bi-specific antibody therapeutic.

The CHOZN expression system is designed to deliver manufacturing-ready robust and stable producing clones with a workflow that minimizes the resources needed to complete a cell line development project. As a result, users are able to quickly evaluate more molecules in their pipeline.

“When compared with alternate expression systems, our CHOZN system offers a turnkey solution that consistently delivers shortened development timelines,” said Udit Batra, chief executive officer, MilliporeSigma.

MilliporeSigma’s CHOZN expression system is based on a GS -/- Chinese hamster ovary (CHO) cell line.

“With only two scientists in our cell science department, we were able to generate more than 10 stable cell lines using this platform in a single year,” said Camilla Wang, scientist, SystImmune. “The CHOZN platform outperformed other systems in many ways. It is easy to use, requires less time to generate final single cell clones, and most of all, the expression level is consistently higher compared to the other approaches.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters